Published in Lab Business Week, April 24th, 2005
As a cofounder of AmpliMed, Hersh led the rediscovery of Amplimexon (imexon inj.) as an anticancer drug. Amplimexon is now the lead drug candidate in AmpliMed's clinical development portfolio. As executive VP, Hersh will assume full responsibility for the planning and execution of all AmpliMed's clinical and scientific development programs.
Morrison brings more than 2 decades of experience in operations, finance and accounting in the healthcare industry to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.